Survodutide (10 mg Vial) Dosage Protocol

Quickstart Highlights

Survodutide (BI 456906) is an investigational dual GLP‑1/glucagon receptor agonist under development for obesity and metabolic liver disease^[1]^[2]. In phase 2 trials, once‑weekly subcutaneous dosing (0.6–4.8 mg) produced dose‑dependent weight loss of 12.5–14.9% versus placebo over 46 weeks^[1]. This educational protocol presents a once‑weekly subcutaneous titration approach using a practical dilution for clear insulin‑syringe measurements.

Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL (5000 mcg/mL) concentration.

Typical weekly range: 0.6–6.0 mg once weekly (gradual titration over 10–12 weeks).

Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at ≤−20 °C (≤−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing

Standard / Gradual Titration (2 mL = 5 mg/mL)

Route & Frequency: Subcutaneous injection once weekly (all clinical trials used weekly dosing)^[1]^[2].

Week	Weekly Dose (mg)	Weekly Dose (mcg)	Units (mL)
Weeks 1–2	0.6 mg	600 mcg	12 units (0.12 mL)
Weeks 3–4	1.2 mg	1200 mcg	24 units (0.24 mL)
Weeks 5–6	1.8 mg	1800 mcg	36 units (0.36 mL)
Weeks 7–8	2.4 mg	2400 mcg	48 units (0.48 mL)
Weeks 9–10	3.6 mg	3600 mcg	72 units (0.72 mL)
Weeks 11–12	4.8 mg	4800 mcg	96 units (0.96 mL)
Week 13+	6.0 mg	6000 mcg	120 units (1.20 mL)*

*Note: The 6.0 mg maintenance dose (120 units / 1.20 mL) exceeds a standard 100‑unit (1 mL) insulin syringe. Use a 1 mL or 3 mL Luer‑lock syringe with appropriate needle, or administer as two separate injections.

Reconstitution Steps

Draw 2.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week weekly protocol with gradual titration.

Peptide Vials (Survodutide, 10 mg each):

8 weeks ≈ 2 vials (~17 mg total)
12 weeks ≈ 4 vials (~39 mg total)
16 weeks ≈ 7 vials (~63 mg total)

Insulin Syringes (U‑100) or 1 mL Luer‑lock Syringes:

Per week: 1 syringe (once weekly)
8 weeks: 8 syringes
12 weeks: 12 syringes
16 weeks: 16 syringes

Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.

8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
16 weeks (7 vials): 14 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each week.

Per week: 2 swabs
8 weeks: 16 swabs
12 weeks: 24 swabs
16 weeks: 32 swabs → recommend 1 × 100‑count box

View Supplier

Protocol Overview

Concise summary of the once‑weekly regimen.

Goal: Support metabolic improvement and weight management through dual GLP‑1/glucagon receptor activation^[1]^[3].

Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as studied in phase 3 trials).

Dose Range: 0.6–6.0 mg weekly with gradual titration over 10–12 weeks.

Reconstitution: 2.0 mL per 10 mg vial (5 mg/mL) for accurate unit measurements.

Storage: Lyophilized frozen; reconstituted refrigerated; protect from light and avoid freeze–thaw.

Research Disclaimer